The firm also said this week that it plans to submit data to the FDA from an adjuvant trial of giredestrant in ER-positive, HER2-negative breast cancer.

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

The House of Lords science and technology committee seeks answers to questions regarding the implementation of treatments like CAR T-cell and gene therapies.

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

After a data monitoring committee saw increased risk of secondary blood cancers in the SYPHONY-1 trial, the firm will stop selling the drug for follicular lymphoma and sarcoma.

The company plans to combine the CAR designs with its in-house delivery platform to advance its in vivo CAR-M therapies toward clinical studies.

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

Day One received accelerated approval in the US in 2024 for Ojemda to treat pediatric low-grade glioma with a BRAF fusion or rearrangement or BRAF V600 mutation.

Allarity Therapeutics said on Friday it has closed a $20 million non-convertible debt financing transaction with venture capital firm Streeterville Capital. The financing is structured as a note ...

The deal could be worth more than $1 billion, if all genetic targets identified lead to approved therapeutics.

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were poorly differentiated.